The Food and Drug Administration is preparing to authorize the vaccine. Pfizer-BioNTech Covid-19 in adolescents aged 12 to 15 by early next week, according to federal officials familiar with the agency’s plans, open the nation’s vaccination campaign to millions of Americans.
The news is highly anticipated: active parents are counting down several weeks since Pfizer announced results on a teenage trial that showed the vaccine was at least as effective in that age group as in. adult Child immunization is also the key to improving immunity in the population and reducing the number of hospitalizations and deaths.
The approval could come as early as later this week, according to federal officials who did not give their names because they were not authorized to speak in public. If allowed, the Centers for Disease Control and Prevention’s Vaccine Advisory Panel will meet the following day to review clinical trial data and make recommendations for the use of the vaccine in adolescents.
The purging will be a major breakthrough in the nation’s vaccination campaign, and it will be welcome news for parents looking to protect their children during summer events and ahead of the semester next school year.
Pfizer reported weeks ago that no adolescents in clinical trials received the vaccine to develop symptomatic infections, a sign of a critical precaution.The company announced in late March that volunteers produced an antibody response that Strong and experienced with side effects seen in people aged 16 to 25 years.
Stephanie Caccomo, a spokesman for the Food and Drug Administration, said she could not comment on the timing of the move.
“We can assure you that we are processing this request as quickly and transparently as possible,” she said.
More than 100 million adults have been fully vaccinated. But the grant will come in the middle of a sensitive and complex push to reach 44 percent of adults who are still hesitant about firing or not being able to reach it.
As the world calls for surplus vaccines made in the United States, use Pfizer-BioNTech In adolescents, it may raise the question of whether supply should be targeting age groups, which so far seems to have been largely spared from Covid-19’s intense competition.
“I think we need to have a national and global conversation about the ethics of vaccinated children who are at low risk for serious viral complications when there is not enough vaccine in the world to protect at-risk adults. This is because of the high levels of mortality, ”said Jennifer Nuzzo, epidemiologist at the Johns Hopkins Center for Health Security.
President Biden has come under increasing pressure to supply some of the country’s vaccines, and even in the federal government, some officials have urged the administration to decide soon how much vaccines will be needed so that the doses will not expire. Or it was shipped to the state and not used. The federal government bought 700 million doses of the federally-licensed vaccine for delivery before the end of July, beyond the necessity of covering all Americans.
The country’s current vaccine volumes are high.As of Monday, about 65 million doses were delivered but they were not received, including nearly 25 million Pfizer-Bio-Tech vaccines. Millions of doses and 10 million doses of Johnson & Johnson, according to figures compiled by the Center for Disease. Control and prevention Both Pfizer and Moderna vaccines require two doses.
The dosage of Pfizer-BioNTech Tens of millions of increases, worth about three weeks, according to one federal official, have been produced and are in various stages of preparation pending final testing before delivery.
Moderna expects results soon from clinical trials involving adolescents aged 12 to 17, followed by results for children 6 months to 12 years old during the second half of this year.